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The canine luteal phase exhibits several peculiarities compared with other species. In
early diestrus, the corpus luteum (CL) is, at least in part, independent of gonadotropins,
and prostaglandins (PGs) appear to be among its main regulators. This was also
observed with the inhibition in vivo of COX2, when also transcriptional capacity,
vascularization and immune-related factors were affected. Here, we aimed to further
investigate the potential effects of PGs withdrawal on the CL transcriptome by performing
deep RNA sequencing (RNA-Seq). Samples from a previous in vivo study were used;
bitches were treated for 5, 10, 20, or 30 days after ovulation with firocoxib (Previcox®),
a PTGS2/COX2 inhibitor, or a placebo. Analysis of results was performed with
SUSHI (framework from FGCZ) and with pathways and functional networks analyzers.
Time-dependent effects were also investigated and used for quality control. More highly
represented differentially expressed genes (DEGs, P < 0.01, FDR < 0.1) in the early CL
(days 5 and 10) referred to proliferation and immune system, while in the mature CL (days
20 and 30) they were related with steroidogenesis. The absence of genes concomitantly
affected by the treatment at all time-points suggested stage-dependency in the observed
effects. Little effect was observed on days 5 and 10. Day 20 had the highest number
of DEGs (n = 1,741), related with increased immune response. On day 30, DEGs found
(n= 552) referred to decreased steroidogenesis and vascularization. Our results suggest
the presence of strong compensatory effects in the early CL and multidirectional effects
toward gonadotropin-dependency of the CL after COX2 inhibition.
Keywords: canine (dog), corpus luteum, prostaglandins, transcriptome (RNA-seq), diestrus
Tavares Pereira et al. Canine Luteal Transcriptome After COX2-Inhibition
INTRODUCTION
The corpus luteum (CL) has a central role in pregnancy through
its production of progesterone (P4). In dogs, it plays an even
more prominent role because it regulates the entire diestric phase.
Indeed, the absence of placental steroidogenic activity in this
species makes the CL the sole source of pregnancy-supporting P4
(1, 2). Following exceptionally strong preovulatory luteinization
(3), the CL continues to develop following ovulation. As in
other species, this is supported by the formation of a dense
vascular network (4, 5). Serum P4 levels vary greatly among
animals and peak between days 15 and 30 after ovulation. Shortly
thereafter, luteal function starts to diminish, accompanied by
decreasing levels of P4 and signs of cellular degeneration (6–
8). The function of the CL is actively terminated in pregnant
bitches shortly before parturition (around day 60 after ovulation)
during prepartum luteolysis. This is associated with increased
circulating prostaglandin (PG)F2α, apparently produced by the
fetal placenta (1, 9–12). Interestingly, no such active mechanism
is observed in the absence of pregnancy (12, 13). There is
no uterine luteolysin in non-pregnant dogs and hysterectomy
does not affect CL function (12, 13). Consequently, non-
pregnant bitches present a physiological pseudopregnancy, with
circulating P4 levels similar to those in pregnant animals (14, 15).
It appears thus, that in lacking an active luteolytic principle, the
CL life span of non-pregnant dogs is regulated by some intrinsic
regulatory mechanisms. At the regulatory level, the canine CL
also presents some species-specific peculiarities compared with
other domestic animals. Both LH and prolactin (PRL) have
luteotropic roles in the canine CL (16–18). However, PRL
appears to be the predominant factor and appears to be required
for CL maintenance starting around day 25 after ovulation
(19, 20). It is noteworthy that ablation of the hypophysis
had less effect on CL function in the first 2–4 weeks after
ovulation (17). Consequently, the canine CL presents a transitory
independence on gonadotropins in its earlier stages, progressing
to a gonadotropin-dependent stage at mid-diestrus, with PRL
then acting as the predominant luteotropic factor (17, 18, 20).
The initial observation of increased expression of
COX2/PTGS2 and PGE2 synthase (PTGES) in early CL stages
suggested PGs as possible important regulators of this organ in
the dog (21, 22). Further investigations showed direct effects
of PGE2 in early canine luteal cells, in which it could increase
steroidogenic acute regulatory (STAR) protein expression and
P4 production (23). Following these clues, the effects of PGs on
CL function were explored in vivo (3, 24). For this, firocoxib
(Previcox, Merial Ltd.), a specific inhibitor of COX2, was used
to treat bitches from the day of ovulation up to 30 days later,
with the aim of causing functional withdrawal of PGs (3, 24).
In fact, the expression of PTGES and intra-CL levels of PGE2
and PGF2α were significantly decreased by this treatment (3).
It also affected the steroidogenic capacity of the CL (decreased
expression of 3βHSD and STAR), and suppressed the levels of
circulating P4 (3, 24). Furthermore, the decreased nuclear size
of luteal cells induced by this treatment was related to their
decreased transcriptional capacity (24). These observations
showed a causality between COX2 and the PTGES-dependent
synthesis of PGE2 in the CL and established PGs as important
modulators of CL function (3, 24).
It appears, however, that PGs might have broader effects on
the regulation of CL function in addition to steroidogenesis.
COX2 inhibition decreased the expression of the PRL receptor
(PRLR) while, in parallel, PGE2 could increase the expression of
PRLR in isolated canine luteal cells (3). This suggested an indirect
role of PGE2, through the enhancement of PRLR expression, to
support the luteotropic function of PRL. Based on this, and on the
fact that PGE2 could also increase the expression of endothelin
receptor B (ETB; important vasodilator) (25), the effects of PGs
withdrawal on luteal vascular and immune factors were further
investigated (26). The stabilization of blood vessels was negatively
affected by the treatment, while the expression of different pro-
inflammatory factors was increased (26). Concomitantly, the
presence of strong compensatory effects was implied.
Considering the peculiarities of the canine luteal phase, the
present study aimed to investigate additional potential effects
of withdrawal of PGs on CL physiology. For this, we used
samples from a previously reported in vivo study (3, 24, 26),
and performed a deep RNA sequencing (RNA-Seq) by applying
Next Generation Sequencing (NGS) technology. With this
approach, we expected to provide deeper understanding of the
importance of PGs at different stages of CL development: its early
gonadotropin-independence, then its transition to dependence
on hypophyseal hormones, and finally the dependence of the
mature CL mainly on PRL. Time-dependent changes in the
CL transcriptome associated with its development were also
investigated in control samples.
MATERIALS AND METHODS
Tissue Samples
This is a follow-up study utilizing tissue material collected in
preceding in vivo studies (3, 24, 26). Animal experiments were
approved by the responsible ethics committee (permit 54/2008)
of the University of Warmia and Mazury in Olsztyn, Poland.
Briefly, mixed-breed bitches of different ages (2–7 years old)
were monitored by vaginal cytology and P4 measurements for
the onset of spontaneous estrus. The day when circulating P4
levels exceeded 5 ng/ml was considered the day of ovulation (day
0). Animals were then randomly assigned to four control and
four treated groups, receiving orally and daily either a placebo
or 10 mg/kg of firocoxib (Previcox, Merial Ltd), respectively.
Treatment wasmaintained for 5, 10, 20 or 30 days after ovulation.
Ovaries were collected by ovariohysterectomy on the last day
of treatment. Corpora lutea were dissected from surrounding
ovarian tissue and preserved in RNAlater at –80◦C until further
use, as described before (23).
RNA Isolation and Purification
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to
isolate total RNA, following the manufacturer’s instructions.
A primary evaluation of RNA purity and concentration
was performed with a NanoDrop 2000C spectrophotometer
(ThermoFisher Scientific AG, Reinach, Switzerland). Further
purification of RNA was performed with the RNeasy Mini Kit
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(Qiagen GmbH, Hilden, Germany), using the RNA Cleanup
protocol provided. RNA integrity was assessed with the Agilent
2200 TapeStation System. RNA integrity numbers (RIN) ranged
from 8.0 to 9.8.
RNA-Sequencing and Data Evaluation
Next Generation Sequencing (NGS, RNA-Seq)
Sequencing of RNA with NGS was performed to obtain a
quantitative evaluation of gene expression. A total of 32 samples
available for this follow-up study were allotted to the following
groups: n= 5 for day 5 control, n= 4 for day 5 treated, n= 4 for
either day 10 control and day 10 treated, n = 3 for either day 20
control and day 20 treated, n= 4 for day 30 control and n= 5 for
day 30 treated. RNA-Seq was performed on n= 4 animals/group
(control and treated) from days 5, 10, and 30, and n = 3
animals/group from day 20 after ovulation. Library preparation,
cluster generation and sequencing were performed as previously
described (27). All samples were processed at the same time to
avoid possible batch effects. In brief, the Qubit (1.0) Fluorometer
(Life Technologies, Carlsbad, CA, USA) and Bioanalyzer 2100
(Agilent, Waldbronn, Germany) were used to evaluate the
quantity and quality of isolated RNA. To be processed further,
samples needed to have a 260/280 nm ratio between 1.8 and
2.1 and a 28S/18S ratio within 1.5–2.0. In the succeeding
steps, the TruSeq RNA Sample Prep Kit v2 (Illumina, Inc., San
Diego, CA, USA) was used. Total RNA samples (100–1,000
ng) were enriched by poly-A selection and reverse-transcribed
to obtain double-stranded cDNA. Additionally, fragmentation,
end-repair and polyadenylation steps were performed on cDNA
samples before ligation of TruSeq adapters containing the index
for multiplexing. PCR was used for selective enrichment of
fragments containing TruSeq adapters on both ends, and the
quality and quantity of the enriched libraries obtained were
assessed with the Qubit (1.0) fluorometer and Caliper GX
LabChip GX (Caliper Life Sciences Inc., Hopkinton, MA, USA).
Finally, libraries were normalized to 10 nM in Tris-Cl 10mM
with Tween 20.
Cluster generation was performed with 2 nM of pooled
normalized libraries on the cBOT System with the TruSeq
PE Cluster Kit v4-cBot-HS or TruSeq SR Cluster Kit v4-
cBot-HS (Illumina, Inc). Sequencing was performed with the
Illumina HiSeq4000 with single end 125 bp using the TruSeq
SBS Kit v4-HS (Illumina, Inc.). The raw data (.fastq files)
obtained were used for downstream analysis. Additionally,
they were also deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession
number GSE130369.
Data Analysis
The initial analysis of data was performed with the framework
SUSHI (28, 29), developed by the Functional Genomics Center
of Zurich (FGCZ ETH/UZH, Zurich, Switzerland). Spliced
Transcripts Alignment to a Reference (STAR) software was used
to align the RNA-Seq dataset (30) to a reference canine genome,
the Ensembl genome build CanFam3.1 (http://www.ensembl.
org/Canis_familiaris/Info/Index). Gene expression values were
obtained with the function featureCounts from the R package
Rsubread (31). A minimum average of 10 reads in at least one
group of replicates was required to consider a gene as detected.
After reads counting, initial quality control and explorative
analysis were performed with the SUSHI framework.
For differential expression analysis different contrasts
(pairwise comparisons) were defined and gene differential
expression for each contrast was assessed with the generalized
linear model approach from the Bioconductor package DESeq2
(32). This was performed as previously described (27), using the
Wald test to assess the significance of differential expression.
Next, correction of multiple testing was obtained with the
Benjamini-Hochberg algorithm that computes False Discovery
Rate (FDR, adjusted P-value). Finally, thresholds of P-value <
0.01 and adjusted P-value < 0.1 (i.e., FDR < 10%) were applied.
The complete differentially expressed genes (DEGs) lists obtained
for each contrast were used for downstream analyses and are
provided in Supplemental Table 1 (for time-dependent effects)
and Supplemental Table 2 (for treatment-induced effects).
Functional characterization of DEGs for each contrast was
performed by identifying different functional terms, resorting
to available bioinformatics resources. The identification of over-
represented functional categories (i.e., gene ontologies) and
their enrichment scores were calculated using the web-based
Panther software [http://pantherdb.org, (33)]. This analysis
was further supported and complemented with the web-based
software Enrichr [http://amp.pharm.mssm.edu/Enrichr/, (34)].
The identification and visualization of enriched functional
biological networks was obtained with the application ClueGO
v2.5.1 (35) for the software platform Cytoscape v3.6 (36). The
software Ingenuity Pathway Analysis (IPA, Qiagen, Redwood
City, CA, USA) was used to predict the most significantly affected
canonical pathways and identify possibly involved upstream
regulators. Lists of up to 10 representative genes involved
with particular functional terms (gene ontologies, functional
networks, canonical pathways and upstream regulators) from
each contrast are presented in Supplemental Table 3. In
addition, Venn diagram was generated to identify DEGs
concomitantly affected by treatment in different contrasts. For
this analysis, the thresholds were defined for P-value < 0.01
and fold-change for up- (log2Ratio ≥ 1) and down-regulation
(log2Ratio < −1). Full lists of DEGs used as input for Venn
diagram and genes present on each intersection are provided in
Supplemental Table 4.
Expression of Selected Target Genes by
Semi-quantitative Real-Time TaqMan
qPCR
Further validation of the RNA-Seq data obtained and
analysis of specific functional pathways suggested by our
analysis were performed through evaluation of the mRNA
expression of 20 selected candidate target genes, by semi-
quantitative real-time (TaqMan) qPCR. All available samples
were used for qPCR experiments (n = 32). A complete
list of primers used, TaqMan probes and pre-designed (i.e.,
commercially-available) TaqMan systems is presented in Table 1.
Self-designed primers and 6-carboxyfluorescein (6-FAM) and
6-carboxytetramethylrhodamine (TAMRA) labeled probes
were designed and ordered from Microsynth AG (Balgach,
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TABLE 1 | List of gene symbols, corresponding gene names and TaqMan systems used for real time qPCR.
Gene Name Accession number Primer sequence Product
length (bp)
IDO1 Idoleamine 2,3-dioxygenase 1 XM_532793.5 Forward 5′-TGA TGG CCT TAG TGG ACA CAA G-3′ 116
Reverse 5′-TCT GTG GCA AGA CCT TTC GA-3′
TaqMan probe 5′-CAG CGC CTT GCA CGT CTG GC-3′
SULT1E1 Sulfotransferase family 1E MK728829 Forward 5′-AAC AGA TGG CAT CTC CTA GAG TAG TG-3′ 100
member 1 Reverse 5′-CGG CAA AGA TAG ATC ACC TTA CAG T-3′
TaqMan probe 5′-CCA TCT GCC AGT TGA ACT TCT TCC AGC C-3′
TBXAS1 Thromboxane A synthase 1 XM_005629559.1 Applied Biosystems, prod. no. Cf01022701_m1 105
PTGDS Prostaglandin D synthase NM_001003131.1 Applied Biosystems, prod. no. Cf02622002_m1 85
TGFβ1 Transforming growth factor beta 1 NM_001003309.1 Applied Biosystems, prod. no. Cf02623324_m1 83
TGFβR1 Transforming growth factor beta
receptor 1
XM_014117881.1 Applied Biosystems, prod. no. Cf02687913_m1 110
ICAM1 Intercellular adhesion molecule 1 NM_001003291.1 Applied Biosystems, prod. no. Cf02690470_u1 124
NODAL Nodal growth differentiation factor XM_546146.3 Applied Biosystems, prod. no. Cf02711306_u1 149
FAS Fas cell surface death receptor XM_005636650.1 Applied Biosystems, prod. no. Cf02651136_m1 118
FASLG Fas ligand NM_001287153.1 Applied Biosystems, prod. no. Cf02625215_s1 89
NFκB1 Nuclear factor kappa B subunit 1 NM_001003344.1 Applied Biosystems, prod. no. Cf02689968_m1 119
NFκBIa NFKB inhibitor alpha XM_537413.5 Applied Biosystems, prod. no. Cf02741714_m1 129
PDGF B Platelet derived growth factor
subunit B
NM_001003383.1 Applied Biosystems, prod. no. Cf02626637_m1 109
FGF1 Fibroblast growth factor 1 XM_014108102.1 Applied Biosystems, prod. no. Cf02716346_g1 77
FGF2 Fibroblast growth factor 2 XM_003432481.3 Applied Biosystems, prod. no. Cf03460065_g1 147
THBS1 Thrombospondin 1 XM_544610.5 Applied Biosystems, prod. no. Cf02701399_m1 88
PPARγ Peroxisome proliferator activated
receptor gamma
NM_001024632.2 Applied Biosystems, prod. no. Cf02625640_m1 92
EGLN1 PHD2/egl-9 family hypoxia inducible
factor 1
XM_546089.4 Applied Biosystems, prod. no. Cf02713521_m1 115
NR4A1 Nuclear receptor subfamily 4 group A
member 1
NM_001003227.1 Applied Biosystems, prod. no. Cf02719047_s1 113
HSD17B7 Hydroxysteroid 17β dehydrogenase 7 XM_014111264.1 Applied Biosystems, prod. no. Cf02657821_m1 82
PTK2 Protein tirosine kinase 2 XM_005627993.2 Applied Biosystems, prod. no. Cf02684608_m1 104
EIF4H Eukaryotic translation initiation
factor 4H
XM_014114129.1 Applied Biosystems, prod. no. Cf02713640_m1 136
KDM4 Lysine (K)-specific demethylase 4A XM_005629106.2 Applied Biosystems, prod. no. Cf02708629_m1 96
Switzerland). The design of IDO1 primers and probes was
based on published canine CDS sequences while for SULT1E1
molecular cloning of the canine sequence was required and
this was performed by a subcloning approach using the
pGEM-T vector, as described previously (22, 37, 38) (sequence
submitted to GenBank under accession number MK728829).
Commercially-available systems were obtained from Applied
Biosystems. The efficiency of PCR reactions was evaluated to
ensure approximately 100% (39).
Elimination of genomic DNA contamination, reverse
transcription (RT) and semi-quantitative real-time TaqMan
qPCR (RT-qPCR) were performed following the manufacturers’
and our previously published protocols (22, 39). Briefly, total
RNA samples were treated with the RQ1 RNase-free DNase
kit (Promega, Dübendorf, Switzerland) to eliminate possible
genomic DNA contamination. Random hexamers were used
as primers in the subsequent RT reactions, employing reagents
obtained from Applied Biosystems. For RT-qPCR, all samples
were run in duplicates in 96-well optical plates, using autoclaved
water and RNA not subjected to RT (minus-RT control)
instead of cDNA as negative controls. Reactions were run in an
automated fluorometer ABI PRISM 7500 Sequence Detection
System (Applied Biosystems) and were set as follows: initial
denaturation for 10min at 95◦C followed by 40 cycles of 15 s at
95◦C and 1min at 60◦C each. Relative quantification was done
by applying the comparative Ct method (11Ct). RT-qPCR data
were normalized with three reference genes: PTK2, EIF4H, and
KDM4. Based on the RNA-Seq data collected herein, these genes
were found to be stably expressed in all samples examined using
the online tool RefFinder and NormFinder software (40, 41).
Since RT-qPCR data were unevenly distributed, logarithmic
transformation was performed and results are presented as
geometric means (Xg) ± geometric standard deviation (SD).
The evaluation of treatment-induced effects was performed with
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a two-tailed Student’s t-test, comparing the treatment group
with the control group at each time point (day). Additionally,
time-related changes in the expression of target genes were
evaluated in control animals using the Kruskal-Wallis test
(non-parametric ANOVA) followed by Dunn’s test. All statistical
tests were performed with GraphPad 3 (GraphPad Software Inc.,
San Diego, CA, USA) and values of P < 0.05 were considered
statistically significant.
RESULTS
Initial Evaluation of Sequencing Results
Initial exploratory analysis of the sequencing data obtained
was performed with the CountQC app provided in the SUSHI
framework. This function allowed assessment of homogeneity
and correlations between samples, as well as clustering of high
variance features among all samples submitted for RNA-Seq. The
analysis of samples correlationmatrix (Supplemental Image 1A)
indicated the presence of some variation among all sequenced
samples. Based on the analysis of this matrix and gene
expression scatter plots (not shown), samples 10/1 and 30/1
controls, and 10/2 and 30/1 treated with Previcox, were
considered outliers and removed from the dataset for further
analysis. This allowed a more homogeneous correlation between
samples within each group (Supplemental Image 1B). Further
observation of the correlation matrix indicated a higher
homogeneity among samples of each control group compared
with the respective treated groups (Supplemental Image 1B).
This was also suggested by the more homogeneous clustering
of samples and genes visible on the heatmap, with 2,000
genes exhibiting higher variance among control samples
(Supplemental Image 1C) comparedwith the one that contained
all analyzed samples (Supplemental Image 1D). Clustering
observed on the heatmap with the 2,000 genes showing higher
variance among all analyzed samples (Supplemental Image 1D)
also suggested that, apart from effects on the immune system and
negative regulation of cellular processes on day 20, passage of
time appeared to have a higher global impact on CL expression
of these genes than COX2 inhibition. This was further visualized
using a principal component analysis (PCA) plot of the same
2,000 genes with higher variance among all samples (Figure 1).
Thus, samples appeared to be segregated based on time-point of
analysis, with those samples from days 5 and 10 being proximally
distributed on a cluster and samples from days 20 and 30 on
the other side of the plot. The scattered distribution of samples
treated up to day 20 after ovulation indicates stronger effects of
treatment in this group (Figure 1).
Time-Dependent Effects
Samples available for the present study were representative of
different regulatory stages of early CL development, i.e., the
early developing, gonadotropin-independent CL (days 5 and 10),
and the mature CL in transition and during its dependence on
gonadotropins (days 20 and 30, respectively). Close similarity
between samples from days 5 and 10 on the one end, and days
20 and 30 on the other end, was also suggested from the PCA
plot (Figure 1). Therefore, when evaluating the effects of time
on the CL transcriptome, samples were grouped accordingly
with differential expression analysis (pairwise comparison) being
performed for the contrast “Days 20+30 control over days 5+10
control.” This analysis was performed using the DESeq2 package
for Bioconductor and genes were assumed to be differentially
expressed if P < 0.01 and FDR < 0.1. Of the total set of
19,856 genes, 13,332 genes were considered expressed (above
the threshold of 10 reads per gene). DEGs accounted for 3,484
features with 1,681 being up- and 1,803 down-regulated at days
20+30 compared with the early developing CL (days 5+10;
Table 2, Figure 2A). A detailed list of all DEGs affected by time
is provided in Supplemental Table 1. Additional representation
of DEGs in Volcano plots, filtered by FDR < 0.1 and log2Ratio
> 0.5, is provided in Supplemental Image 2A. Following this,
functional characterization of DEGs was performed. First, the
pairwise comparison was classified according to Gene Ontology
(GO) terms related to the domain biological process (BP).
Panther software was used to calculate enrichment scores
for each term, and results were further corroborated with
Enrichr. Lists of up to ten (n = 10) representative genes for
different functional terms, as well as upstream regulators and
networks identified in the following steps, are presented in
Supplemental Table 3.
Genes more highly represented at early CL stages (days
5+10) compared to days 20+30 were strongly associated with
(Figure 2A, Supplemental Table 3): cell-cell adhesion (P =
2.40E-3), locomotion (P = 1.28E-3), immune system process
(P = 1.27E-3), metabolic process (P = 9.67E-4) and cellular
process (P= 2.73E-4). On the other hand, functional terms over-
represented in the mature CL (days 20+30) included (Figure 2A,
Supplemental Table 3): fatty acid biosynthetic process (P =
1.26E-3), fatty acid metabolic process (P = 2.96E-4), lipid
metabolic process (P= 1.12E-6), phospholipid metabolic process
(P = 2.35E-3), protein localization (P = 1.64E-3), intracellular
protein transport (P = 1.04E-3), transport (P = 3.12E-5) and
localization (P = 1.22E-4).
Using as input the lists of upregulated and downregulated
DEGs for this contrast (Supplemental Table 1), enriched
functional networks were grouped and visualized with the
ClueGO plug-in for the platform Cytoscape (Figure 2B,
Supplemental Table 3, Supplemental Image 3A). Among the
more highly represented functional networks observed on days
5 and 10 were those referring to cell signaling and metabolism,
extracellular matrix, apoptosis and, in greater numbers, networks
related to immune function (Figure 2B, Supplemental Table 3).
On the other hand, networks mainly observed on days 20 and
30 were associated with intracellular transport and (lipids)
metabolism (Supplemental Table 3, Supplemental Image 3A).
The prediction of the most significantly affected signaling
pathways was obtained from IPA software by using the list of
DEGs as input (P < 0.01, FDR< 0.1). Among the most enriched
canonical pathways predicted to be activated by the passage of
time were those related to (Supplemental Table 3): cholesterol
synthesis/steroidogenesis (superpathway of cholesterol
biosynthesis, P = 4.90E-5; cholesterol biosynthesis I, P =
1.20E-4; cholesterol biosynthesis II, P = 1.20E-4; and cholesterol
biosynthesis III, P = 1.20E-4). On the other hand, among
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FIGURE 1 | Principal component analysis (PCA) plot of all samples showing the 2,000 genes that presented higher variance. Distribution of samples appears to be
mainly based on the effect of time (highlighted by red bar separating samples from days 5 and 10 from samples from days 20 and 30). Samples distribution and
scattering also suggest stronger effects of treatment on day 20 than on the other time points studied.
TABLE 2 | Summary of differential expression analysis (pairwise comparison) for all selected contrasts investigated in the present study.
Contrasts Days 20+30C over
days 5+10 C
Day 5T over
day 5 C
Day 10T over
day 10 C
Day 20T over
day 20 C
Day 30T over
day 30 C
Total DEGs (P < 0.01,
FDR < 0.1)
3,484 74 2 1,741 552
Number of genes with
counts above threshold
(10 reads per gene)
13,332 13,428 13,280 13,477 13,187
Upregulated genes 1,681 47 1 1,146 306
Downregulated genes 1,803 27 1 595 246
significant pathways that were predicted to be inhibited
by time were those related to (Supplemental Table 3): cellular
proliferation (EIF2 signaling, P= 7.94E-16; mTOR signaling, P=
3.98E-12), cell cycle (cyclins and cell cycle regulation, P = 3.63E-
7), ECM production (inhibition of matrix metalloproteases,
P = 1.86E-4) and immune function (leukocyte extravasation
signaling, P = 3.55E-8; acute phase response signaling, P =
5.89E-6; IL8 signaling, P = 3.63E-5; chemokine signaling,
4.68E-5; dendritic cell maturation, P = 1.8E-4).
The analysis of DEGs with IPA allowed additional
identification of upstream regulators possibly affecting
expression of the DEGs obtained. Among the predicted
upstream regulators, the following factors were identified:
transforming growth factor β 1 (TGFβ1, P = 7.27E-33), tumor
necrosis factor (TNF, P = 5.88E-26), beta-estradiol (P = 3.08E-
22), platelet-derived growth factor BB (PDGF BB, P= 1.08E-18),
interferon gamma (INFγ, P = 3.47E-15), progesterone (P4, P =
3.86E-15), insulin growth factor 1 (IGF1, P = 3.85E-13), nuclear
factor kappa B inhibitor alpha (NFκBIα, P = 5.86E-13) and
prostaglandin (PG) E2 receptor 2 (PTGER2/EP2, P = 9.5E-12)
(Supplemental Table 3).
Treatment-Induced Effects
Differential Expression Analysis (Pairwise
Comparison) and Venn Diagram
The effects of treatment with Previcox on the transcriptome
of CL tissue were assessed by differential expression analysis,
in which treated samples were compared with control samples
at the respective time-points (days 5, 10, 20 and 30). Thus,
the following contrasts were defined: “day 5 treated over day 5
control,” “day 10 treated over day 10 control,” “day 20 treated
over day 20 control,” and “day 30 treated over day 30 control.”
As described for time-dependent effects, the DESeq2 package for
Bioconductor was used to obtain lists of DEGs. The thresholds of
P < 0.01 and FDR< 0.1 were applied to consider a gene as being
differently expressed. For all contrasts, a total of 19,856 genes
were identified; only genes with at least 10 reads were considered
as expressed and included in further analyses. A summary of
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FIGURE 2 | Functional categorization of differentially expressed genes (DEGs) affected at selected time points (contrast “days 20+30 control over days 5+10
control”). (A) Heatmap of 3,484 DEGs in the contrast “days 20+30 over days 5+10 control.” Gradient of high to low expression of each gene relative to average
expression is indicated by red to blue colors. 1,803 genes were more highly expressed in early (days 5 and 10) CL stages whereas 1,681 genes were more highly
expressed in mid-diestrus (days 20 and 30) stages (P ≤ 0.01, FDR ≤ 0.1). Representative overrepresented functional terms in each group of upregulated genes are
listed (statistical details are provided in the text and Supplemental Table 3). Entire list of DEGs is provided as Supplemental Table 1. (B) Functional networks found
for downregulated DEGs from the contrast “days 20+30 control over days 5+10 control.” Overrepresented functional terms of days “5+10 control” are shown.
Redundant or non-informative terms were removed and the networks obtained were manually rearranged. Number of mapped genes is indicated by the node size,
while significance of functional terms is denoted by node color (represented in legend at the right bottom corner). Networks more highly represented on days 5 and 10
control (developing gonadotropin-independent CL) were related to immune function, extra-cellular matrix (ECM), intracellular signaling and apoptosis.
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DEGs analysis is presented in Table 2, while full lists of DEGs
in response to all treatments at every time-point are presented in
Supplemental Table 2.
For the contrast at day 5, after being filtered (P < 0.01,
FDR < 0.1), 74 genes were considered to be DEGs, of which
47 were upregulated and 27 downregulated after treatment.
As for the contrast “day 10 treated over day 10 control,” the
expression of genes varied greatly individually, and resulted in
only 2 DEGs filtered by the applied P-value/FDR thresholds.
Following this low number of DEGs found at day 10, no
functional characterization could be performed for this contrast.
In the contrast for day 20, 1,741 genes met the criteria of
P < 0.01 and FDR < 0.1, making this the treatment-related
contrast with the highest number of DEGs. Of these DEGs, 1,146
were more highly expressed in the day 20 treated group, while
595 were more highly expressed in the day 20 control group.
Finally, for the contrast “day 30 treated over day 30 control”
552 genes were differently expressed (P < 0.01, FDR < 0.1),
comprising 306 up- and 246 down-regulated features in response
to prostaglandin withdrawal. Further representation of DEGs
(FDR< 0.1; log2ratio> 0.5) for the contrasts “day 5 treated over
day 5 control,” “day 20 treated over day 20 control,” and “day 30
treated over day 30 control” in form of Volcano Plots are shown
in Supplemental Image 2B–D.
In an attempt to identify genes that would be simultaneously
affected by COX2-inhibition at different time-points of the CL
life span, the intersections of DEGs from the contrasts at days
5, 20, and 30 were visualized with a Venn diagram (Figure 3A).
The input DEGs were filtered for P < 0.01 and log2Ratio <
−1 (downregulated) and log2Ratio > 1 (upregulated), and a
complete list of genes from each intersection is provided in
Supplemental Table 4. Thirty-two genes were simultaneously
affected by treatment on days 5 and 20, while 78 were shared
among days 20 and 30. Despite the time difference, 4 genes
were still found to be simultaneously affected on days 5 and 30.
However, no gene was concomitantly affected by prostaglandin
withdrawal at the different time-points.
Functional Annotations, Networks, and Pathways
Further characterization of DEGs for each contrast was
performed by identifying different enriched functional
terms. The analysis flow was similar to the one applied
in differential expression analysis of time-related effects:
functional terms (GOs) were identified with Panther
and Enrichr, functional networks were visualized with
Cytoscape, and prediction of affected canonical pathways
and upstream regulators involved was done by IPA.
For input, DEGs were filtered by P < 0.01 and FDR
< 0.1; lists of representative genes are provided in
Supplemental Table 3.
Contrast “day 5 treated over day 5 control”
The main functional terms related to genes more highly
expressed in treated samples from day 5 were (Figure 3B,
Supplemental Table 3): positive regulation of intracellular
transport (P = 3.48E-8), regulation of cell motility (P = 1.31E-
6), regulation of cell migration (P = 7.40E-6), regulation of
cellular component movement (P = 2.59E-6) and regulation
of locomotion (P = 2.84E-6). Due to low numbers of input
DEGs, no significant gene ontologies could be identified
among the DEGs downregulated by treatment at this early
gonadotropin-independent luteal phase. This also accounts for
the Cytoscape analysis of functional networks from up- and
down-regulated genes.
Enriched pathways predicted to be activated by IPA were
mostly related to (Supplemental Table 3): cytoskeleton/cell
movement/cell division (RhoA signaling, P = 1.10E-6; actin
cytoskeleton signaling, P = 4.07E-5; signaling by Rho family
GTPases, P = 6.31E-5; regulation of actin-based motility by
Rho, P = 1.07E-4). Additionally, the pathways death receptor
signaling (P = 5.50E-6) and leukocyte extravasation signaling (P
= 2.75E-4) were also predicted to be activated by treatment, while
the RhoGDI signaling (P = 5.13E-7) pathway was predicted to
be deactivated. Among the predicted upstream regulators, actin
alpha cardiac muscle 1 (ACTC1, P = 7.59E-6), PDGF BB (P =
3.13E-5), actin alpha 2 (ACTA2, P= 2.1E-4), TNF (P= 2.78E-4),
and TGFβ1 (P = 9.94E-E4) were found (Supplemental Table 3).
Contrast “day 20 treated over day 20 control”
For this contrast, the following main terms more highly
represented in the treated mature CL during its transition to
gonadotropin dependence on day 20 were found (Figure 3C,
Supplemental Table 3): cell proliferation (P = 4.78E-4),
regulation of cell cycle (P = 7.06E-5), cell-cell adhesion (P
= 9.85E-4), locomotion (P = 5.58E-5), response to external
stimulus (P = 1.20E-3), cell differentiation (P = 1.84E-4),
regulation of phosphate metabolic process (P = 2.03E-4),
developmental process (P = 1.93E-5), cellular component
organization or biogenesis (P = 6.12E-4) and metabolic process
(P = 1.46E-3). High functional variation was found for DEGs in
control samples on day 20, yielding only low enrichment scores
without strongly enriched functional terms, and without any
strongly enriched functional networks. This differed from the CL
samples derived from dogs treated for 20 days with Previcox, in
which strongly over-represented networks were found, referring
to cell differentiation, cell death, gene expression, translation and
signaling, hormone regulation and immune function (Figure 4,
Supplemental Table 3).
In response to Previcox treatment, the significant
canonical pathways that were predicted to be activated
(Supplemental Table 3) were related by IPA analysis to cellular
proliferation/growth (EIF2 signaling, P = 5.01E-21; mTOR
signaling, P = 1.86E-9) and immune function (toll-like receptor
signaling, P = 1.66E-4; adrenomedulin signaling pathway, P
= 1.20E-3; and acute phase response signaling, P = 4.37E-3;
NFκB signaling, P = 4.47E-3; IL6 signaling, P = 4.47E-3).
Additionally, the relaxin signaling (P = 4.68E-4) pathway was
also predicted to be activated while the angiopoietin signaling
(P = 4.47E-3) pathway was predicted to be deactivated. The
list of top upstream regulators for the observed effects included
(Supplemental Table 3): β-estradiol (P = 6.66E-23), PDGF BB
(P= 9.63E-20), TGFβ1 (P= 2.26E-15), IL1β (P= 1.1E-14), TNF
(P = 4.27E-14), PGE2 (P = 3.68E-11), NFκBIA (P = 1.45E-10),
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FIGURE 3 | Venn diagram showing the distribution and overlap of differentially expressed genes (DEGs) induced by treatment at different time-points (A). Lists of
DEGs from the contrasts “day 5 treated over day 5 control,” “day 20 treated over day 20 control,” and “day 30 treated over day 30 control” were used as input data.
Thresholds were defined for P-value < 0.01 and fold-change for up (log2Ratio ≥ 1) and downregulated (log2Ratio ≤ −1) genes. No gene was found to be
concomitantly affected by treatment in all groups. Complete list of genes from each contrast and intersection are present in Supplemental Table 4. Heatmap and
overrepresented functional terms present in differentially expressed genes (DEGs) induced by treatment at different studied time-points (B–D). Gradient of high to low
expression of each gene relative to average expression is indicated by red to blue colors. Main significant overrepresented functional terms (gene ontologies) in each
group of upregulated genes are listed (statistical details are provided in the text and Supplemental Table 3). Entire list of DEGs is provided as Supplemental Table 2.
(B) Heatmap of 74 DEGs of the contrast “day 5 treated over day 5 control” and representative significant overrepresented functional terms in “day 5 treated” are
shown. (C) Heatmap of 1,741 DEGs of the contrast “day 20 treated over day 20 control” and representative significant overrepresented functional terms at “day 20
treated”. (D) Heatmap of 552 DEGs of the contrast “day 30 treated over day 30 control” and representative overrepresented functional terms in “day 30 control”.
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FIGURE 4 | Functional networks found in upregulated differentially expressed genes (DEGs) from the contrast “day 20 treated over day 20 control.” Overrepresented
functional terms of “day 20 treated” are shown. Redundant or non-informative terms were removed and the networks obtained were manually rearranged. Number of
mapped genes is indicated by the node size while significance of functional terms is denoted by node color (represented in legend at the right bottom corner).
Networks more highly represented in CL samples from animals treated until day 20 after ovulation were related to gene expression and translation, signaling, hormone
regulation, cell differentiation and death, and immune function.
Fas cell surface death receptor (FAS, P = 1.89E-9) and P4 (P
= 2.14E-9).
Contrast “day 30 treated over day 30 control”
Genes higher expressed in day 30 control samples were
related with the following functional terms (Figure 3D,
Supplemental Table 3): steroid metabolic process (P = 2.32E-4),
lipid metabolic process (P = 1.07E-4), cell adhesion (P =
1.33E-3), localization (P = 1.82E-3) and cell communication (P
= 8.96E-4). No significantly enriched GO and networks could be
found for genes upregulated in response to treatment on day 30,
which was restricted by higher functional variation of identified
DEGs. However, in control samples functional networks related
to nitric oxide synthesis and angiogenesis were found to be highly
enriched (Supplemental Table 3, Supplemental Image 3B).
Interestingly, canonical pathways predicted to be deactivated
by treatment in mature CL at day 30 were related with
(Supplemental Table 3): cholesterol synthesis/steroidogenesis
(superpathway of cholesterol biosynthesis, P = 1.35E-7;
cholesterol biosynthesis I, P = 6.31E-6; cholesterol biosynthesis
II, P = 6.31E-6; cholesterol biosynthesis III, P = 6.31E-6),
immune signaling (acute phase response signaling, P = 1.91E-4;
NFκB signaling, P = 3.47E-4; TGFβ signaling, P = 5.13E-3;
IL8 signaling, P = 6.61E-3; leukocyte extravasation signaling,
P = 8.71E-3) and vascularization (VEGF signaling, P = 3.31E-
3; PDGF signaling, P = 1.48E-3). With regard to cellular
proliferation, the EIF2 signaling (P = 3.16E-13) pathway was
predicted to be activated, while the mTOR signaling (P =
2.63E-7) pathway was predicted to be deactivated. Among
the top upstream regulators predicted with IPA software were
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(Supplemental Table 3): TNF (P = 1.89E-10), peroxisome
proliferator-activated receptor gamma (PPARγ, P = 9.22E-5),
TGFβ1 (P = 9.58E-5), fibroblast growth factor 2 (FGF2, P =
1.44E-4) and NFκBIA (P = 2.25E-4).
Expression of Candidate Target Genes
The expression of candidate genes was investigated by semi-
quantitative (TaqMan) qPCR in 32 samples from the different
available groups. All results for time-dependent and treatment
effects are cumulatively presented in Supplemental Table 5.
Extracted, significant results were prepared for the main
document and are shown in Tables 3, 4. The functional groups
chosen for validation of transcriptional analysis included:
eicosanoid synthases (TBXAS1, PTGDS), immune factors
(TGFβ1, TGFβR1, ICAM1, IDO1, NODAL, FAS, FASLG, NFκB1,
NFκBIA), growth factors (PDGF B, FGF1, FGF2), vascular
regulators (THBS1), hypoxia-related factors (EGLN1/PHD2),
nuclear receptors (PPARG, NR4A1) and steroid-related factors
(HSD17B7, SULT1E1). Expression of all candidate genes was
detected in all tissues and, generally, a good correlation was
found between RNA-Seq and RT-qPCR results. Additionally,
no significant changes in the expression of EGLN1 and PDGF B
could be found in response to treatment or passage of time.
Time-Dependent Effects
Changes in candidate gene expression associated with time were
assessed in control samples. All significant effects observed with
the passage of time (including statistical analysis) are presented
in Table 3. Time-related effects were observed for: TBXAS1(P =
0.0006), PTGDS (P = 0.0153), TGFβR1 (0.0017), ICAM1 (P =
0.0003), FAS (P = 0.0015), FASLG (P < 0.0001), NFκBIA (P =
0.0006), FGF1 (0.0031), FGF2 (P= 0.0032), THBS1 (P< 0.0001),
PPARγ (P = 0.0183) and HSD17B7 (P < 0.0001) (Table 3,
Supplemental Table 5). Despite that P < 0.05 was obtained for
NFκB (P = 0.0408) with the ANOVA test, no significant effect
was obtained in the multiple comparisons test (P> 0.05, Table 3,
Supplemental Table 5).
The expression of most target genes was downregulated with
the passage of time. Expression of TBXAS1, ICAM1, FAS, FASLG,
and THBS1was significantly higher in early developing CL stages
(days 5 and/or 10) and decreased toward CL maturation (days 20
and/or 30). The expression of PTGDS, NFκBIA, and PPARγ was
significantly higher on day 10 than on day 20. TGFβR1 and FGF2
expression was the lowest on day 30 compared with days 5 and
20 or only with day 20, respectively. In a different direction, the
expression of FGF1 significantly increased from day 5 to day 30.
Finally, HSD17B7 had the lowest expression at day 5, increasing
during later stages of CL development.
Treatment-Induced Effects
Effects of Previcox treatment were assessed in all available
samples by comparing expression of candidate genes in treated
and control groups at each time-point (days 5, 10, 20, and
30). No significant changes (P > 0.05) in the expression of
FGF1 and HSD17B7 were obtained in response to treatment in
any of the comparisons studied (Supplemental Table 5), even
if their expression was predicted to be modulated by NGS on
days 30 and 20. Additionally, no significant changes in the
expression of any of the candidate genes could be observed
on day 10 (Supplemental Table 5). In the pairwise comparison
on day 5, TGFβ1 and THBS1 exhibited increased expression
in response to treatment, while FASLG, FGF2 and SULT1E1
were downregulated (for details, including statistical analysis,
see Table 4A). At day 20, higher expression of TGFβR1 and
FGF2 was observed in control samples (Table 4B). In a different
direction, several factors were upregulated by treatment on day
20: TBXAS1, PTGDS, ICAM1, NODAL, FAS, FASLG, NFκB1,
NFκBIA, THBS1, PPARG, NR4A1, and SULT1E1 (Table 4B).
Finally, on day 30, treatment decreased the expression of IDO1
and increased the expression of FGF2 (Table 4C).
DISCUSSION
General Considerations
Among many species-specific regulatory features, the presence
of a transitional gonadotropin independence in the developing
canine CL is certainly one of the most intriguing (17, 20).
It positions the dog as a valuable model for investigating
CL development without the dominant effects of hypophyseal
hormones that are observed, e.g., in livestock (42, 43). As
described previously, PGs, mainly PGE2, are considered to be
among the most important regulators of CL function during its
independence from gonadotropins (3, 23, 24). It also became
apparent that PGE2 might have a broader role in the canine
CL, regulating luteal sensitivity to other hormones (e.g., PRL)
and exerting vasoactive and immunomodulatory actions (3, 25,
26). Consequently, the wide spectrum of direct and indirect
effects of PGs in the canine CL encouraged us to perform
the present NGS-based study. The ultimate goal was to better
understand the different roles that PGs might play in the CL
transcriptome and, thereby, to elucidate other possible regulatory
mechanisms induced by PGs in the CL. Taking advantage of
access to control samples covering the time span between days
5 and 30 after ovulation, i.e., during the development and
maturation of the CL, transcriptional changes were also assessed
in these samples with regard to the effects of time. In agreement
with our previous reports (3, 24, 26), large variations in gene
expression were observed in the CL of Previcox-treated dogs.
This may be at least partially explained by the small number of
animals per group and individual variations in gene expression.
However, as can be seen from the analysis of the sequencing
data presented herein, treatment with Previcox itself seemed to
be an additional cause for these fluctuations. In fact, samples
from control groups showed a higher correlation with each
other than samples from treated groups. This could also be
observed on the heatmap analysis of the 2,000 genes with higher
variance, showing more homogeneous clustering when only
control samples were used. As discussed elsewhere, individual
variations and pharmacokinetics may have played an important
role in the lower homogeneity observed in treated groups (26).
The evaluation of both PCA and heatmap plots also suggested a
more homogeneous clustering of samples divided between early
and mature CL than by application of treatment. It seemed,
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TABLE 3 | Relative gene expression of target candidate genes affected by time in control animals.
Target Group RGE SD+/SD– ANOVA P-value Dunn’s test
TBXAS1 Day 5 control 3.95 1.57/1.12
0.0006
5C vs. 20C – P < 0.05
10C vs. 20C – P< 0.01
10C vs. 30C – P< 0.05
Day 10 control 6.02 8.98/3.6
Day 20 control 1.75 0.86/0.58
Day 30 control 2.25 2.66/1.22
PTGDS Day 5 control 6.17 6.69/3.21
0.0153 10C vs. 20C – P < 0.05
Day 10 control 15.02 18.43/8.28
Day 20 control 4.39 3.95/2.08
Day 30 control 6.74 14.58/4.61
TGFβR1 Day 5 control 6.28 3.51/2.25
0.0017
5C vs. 30C – P< 0.001
20C vs. 30C – P< 0.05
Day 10 control 5.15 6.45/2.86
Day 20 control 6.49 4.86/2.78
Day 30 control 2.85 1.98/1.17
ICAM1 Day 5 control 5.35 10.74/3.57
0.0003
5C vs. 20C – P < 0.01
5C vs. 30C – P < 0.01
10C vs. 20C – P< 0.05
Day 10 control 3.23 1.76/1.14
Day 20 control 1.69 0.9/0.59
Day 30 control 1.83 0.77/0.54
FAS Day 5 control 2.61 1.01/0.73
0.0015
5C vs. 20C –P< 0.01
5C vs. 30C –P< 0.01
Day 10 control 2.33 2.43/1.19
Day 20 control 1.4 0.38/0.3
Day 30 control 1.45 0.77/0.5
FASLG Day 5 control 4.59 2.66/1.68
<0.0001
5C vs. 20C – P < 0.01
5C vs. 30C – P < 0.001
10C vs. 20C – P < 0.05
10C vs. 30C – P < 0.01
Day 10 control 4.2 2.05/1.38
Day 20 control 2.3 0.51/0.41
Day 30 control 1.85 1.13/0.7
NFκB1 Day 5 control 1.63 0.63/0.46
0.0408
No significant effects in
group comparisons
Day 10 control 2.13 1.0/0.68
Day 20 control 1.35 0.72/0.47
Day 30 control 1.41 0.68/0.46
NFκBla Day 5 control 2.4 3.85/1.48
0.0006 10C vs. 20C – P < 0.001
Day 10 control 4.11 6.81/2.56
Day 20 control 1.2 0.33/0.26
Day 30 control 1.75 0.88/0.58
FGF1 Day 5 control 3.2 1.57/1.05
0.0031 5C vs. 30C – P < 0.01
Day 10 control 5.47 8.77/3.37
Day 20 control 4.98 2.05/1.45
Day 30 control 6.45 3.23/2.15
FGF2 Day 5 control 3.63 2.04/1.31
0.0032 20C vs. 30C – P < 0.01
Day 10 control 3.45 2.18/1.34
Day 20 control 4.65 1.46/1.11
Day 30 control 2.22 0.82/0.6
THBS1 Day 5 control 8.91 5.75/3.5
<0.0001
5C vs. 20C – P < 0.001
5C vs. 30C – P < 0.001
Day 10 control 4.85 3.59/2.06
Day 20 control 1.97 1.4/0.82
Day 30 control 2.91 2.45/1.33
PPARγ Day 5 control 2.2 1.28/0.81
0.0183 10C vs. 20C – P < 0.05
Day 10 control 4.08 6.75/2.54
Day 20 control 1.66 0.41/0.33
Day 30 control 1.89 0.9/0.61
HSD17B7 Day 5 control 1.9 1.04/0.67
<0.0001
5C vs. 10C – P < 0.05
5C vs. 20C – P < 0.001
5C vs. 30C – P < 0.001
Day 10 control 4.58 3.53/1.99
Day 20 control 7.7 1.74/1.42
Day 30 control 6.16 8.03/3.48
Relative gene expression (RGE) is presented for each group as the geometric mean and geometric standard deviation (SD). Non-parametric ANOVA (Kruskal-Wallis) analysis was followed
by Dunn’s test. Only results considered statistically significant (P < 0.05) are presented. Blue ANOVA indicates higher gene expression in early control groups (days 5 and/or 10); red
ANOVA indicates higher gene expression in mid-diestrus control groups (days 20 and/or 30); black ANOVA indicates no specific changing pattern between early and mid-diestrus
control groups (i.e., between days 5 and/or 10 and days 20 and/or 30).
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TABLE 4 | Relative gene expression of target candidate genes affected by treatment at each analyzed time-point.
Target gene TaqMan real time PCR NGS results
RGE/contr. SD+/SD– RGE/treat. SD+/SD– P-value P-value Log2 ratio
A. Day 5 treated over control
TGFβ1 1.58 0.4/0.32 2.67 1.84/1.09 0.0017 0.02148 0.4632
FASLG 4.59 2.66/1.68 2.44 1.35/0.87 0.0013 0.03313 −1.4
FGF2 3.63 2.04/1.31 2.14 1.46/0.87 0.009 0.163 −1.136
THBS1 8.91 5.75/3.5 14.07 5.98/4.2 0.0129 0.2279 0.6146
SULT1E1 7.97 7.27/3.8 4.18 4.33/2.13 0.0023 0.003543 3.094
B. Day 20 treated over control
TBXAS1 1.75 0.86/0.58 4.25 4.41/2.17 0.005 0.003262 2.014
PTGDS 4.39 3.95/2.08 28.31 28.06/14.09 <0.0001 7.43E-05 2.637
TGFβR1 6.49 4.86/2.78 2.18 1.91/1.02 0.0013 0.04251 −0.8656
ICAM1 1.69 0.9/0.59 16.76 23.31/9.75 <0.0001 4.21E-07 3.765
NODAL 4.5 11.64/3.24 262.07 227.7/121.8 <0.0001 2.98E-09 5.04
FAS 1.4 0.38/0.3 2.6 1.01/0.73 0.0003 0.006776 0.8808
FASLG 2.3 0.51/0.41 5.73 3.05/1.99 <0.0001 0.008149 2.836
NFκB1 1.35 0.72/0.47 2.42 1.04/0.73 0.0064 0.005073 0.932
NFκBla 1.2 0.33/0.26 5.69 2.62/1.8 <0.0001 7.41E-10 2.01
FGF2 4.65 1.46/1.11 2.37 2.41/1.19 0.0162 0.4982 −0.6664
THBS1 1.97 1.4/0.82 12.77 10.58/5.79 <0.0001 0.0007533 2.55
PPARγ 1.66 0.41/0.33 5.56 7.24/3.14 0.0006 7.94E-08 2.283
NR4A1 4.96 3.03/1.88 43.73 44.88/22.15 <0.0001 2.11E-07 3.616
SULT1E1 6.62 6.63/3.31 17.15 32.76/11.25 0.0396 0.001586 2.63
C. Day 30 treated over control
IDO1 4.75 6.1/2.67 1.63 0.97/0.61 0.0003 0.0002207 −3.172
FGF2 2.22 0.82/0.6 3.57 2.36/1.42 0.0088 0.765 −0.2163
Relative gene expression (RGE) is presented for each group (contr., control group; treat., treated group) as the geometric mean and geometric standard deviation (SD+/SD–). Student’s
t-test was applied to test the effect of treatment at each analyzed time-point. Only results considered statistically significant (P < 0.05) are presented. Blue t-test indicates higher gene
expression in the control group, while red indicates higher gene expression in treated groups.
thus, that time had a great impact on the transcriptional changes
observed among the samples studied.
Time-Dependent Effects
Showing homogenous distribution of gene expression, with
a clear distinction between the early and mature CL, time-
dependent effects were examined in control samples and
additionally served for quality control. When compared with
developing CL (days 5 and 10), more highly represented
genes in the mature CL (days 20 and 30) related to lipid
biosynthesis/metabolism. The canonical pathways predicted
to be upregulated at this stage were related to cholesterol
biosynthesis. Cholesterol is a substrate required for steroid
hormone synthesis. An increase of its production is probably
required for the observed increased steroidogenic output from
the CL at this time. As also confirmed by the qPCR analysis,
the expression of HSD17B7 (known as PRLR-associated protein)
was found to increase with maturation of the CL. Together with
other isoforms of 17βHSD, this enzyme is responsible for the
conversion of estrone into estradiol, a more potent estrogen
(44, 45). Considering the high variation in circulating 17β-
estradiol (E2) during the canine diestrus (1), together with the
concomitantly increased expression of aromatase (CYP19) (46),
it is plausible that the observed increase in HSD17B7 expression
could be involved in the local provision of estrogens in the canine
CL. Reflecting the increasing steroidogenic capacity of the CL,
following their initial post-ovulatory decrease, E2 levels increase
during the course of diestrus in the dog, roughly following the
P4 secretion profiles (13, 47). The expression of the estrogen
receptors, ESR1/ERα and ESR2/ERβ, has been confirmed in
the canine CL (46). Nevertheless, the involvement of estrogens
in regulating canine CL function remains underexplored, even
though some attempts were made to shed light on the underlying
mechanisms (6, 46). Functional terms more highly represented
on days 5 and 10 after ovulation were mainly related to immune
function and proliferative mechanisms, such as locomotion, cell-
cell adhesion, extracellular matrix organization, and regulation
of the ERK1/2 cascade. Accordingly, pathways related to cell
cycle, proliferation and immune function, were predicted to
be inactivated following CL maturation, i.e., at days 20/30 of
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the CL lifespan. The apparently increased immune activity in
the developing canine CL is in accordance with its previously
reported increased infiltration by macrophages, monocytes and
lymphocytes at this stage (48, 49). Furthermore, regarding
immune regulation, TNF was among the top predicted upstream
regulators involved in the CL transcriptomic changes observed
in response to time. Similarly, an increased expression of TNFα
and its receptor TNFR2 on day 5 compared with mature CL
stages was reported previously (26). Here, the expression of FAS
and FASLG, factors belonging to the TNF superfamily, was also
found to be more highly expressed in early than in mature CL at
mid-diestrus (days 5/10 over 20/30). Their increased expression
at that time was corroborated by the qPCR results. The role
of the FAS/FASLG system in luteolysis, as extrinsic inducers of
apoptosis, has been widely described in different species (50–
54). With regard to the early CL, FAS was also observed to
be increased in bovine CL as early as at day 5 after ovulation,
provoking the question of possible non-apoptotic FAS signaling
in regulating CL function (55). Indeed, FAS has been shown
to affect some downstream non-apoptotic signaling pathways,
such as NFκB (56). Thus, although the role of FAS/FASLG in
the developing CL is still unknown, it could be also related
with immune-mediated tissue reorganization and proliferation.
Similar to FAS/FASLG, thrombospondins (THBS) have been
associated with luteolytic events, responding to PGF2α and acting
as anti-angiogenic factors by inhibiting the pro-angiogenic FGF2
(57, 58). Similar to the rat (59), and as also found by our qPCR
analysis, increased expression of THBS1 was detected in early CL
stages and decreased toward mid-diestrus in mature CL (days 20
and 30). Within the early CL stage, an intense angiogenic activity
is observed. Thus, the increased expression of THBS1 appears
paradoxical and is not fully understood. It appears plausible that
THBS1 could act as a limiter of vascular overgrowth, as suggested
by others (59). However, it should be mentioned that the protein
availability of this factor, as well as the availability of its receptors,
were not investigated in the present study, but certainly merit
further attention.
Regarding eicosanoids, modulation of CL function is
classically seen as a balance between the luteotropic function
of PGE2 and the luteolytic activity of PGF2α. In the canine
CL, the expression of PGE2 synthase (PTGES) and PGE2
receptor 2 (PTGER2/EP2) decreases with the passage of time
(21). This expression pattern could explain inhibition of
the eicosanoid signaling pathway predicted by IPA software.
Accordingly, similar time-dependent effects were observed
herein in the expression of TBXAS1 and PGD2-synthase
(PTGDS), which decreased from the early to the mid-luteal
phase in the transcriptional analysis (further confirmed by
qPCR). Both eicosanoids have been predominanty characterized
in other systems. Thus, whereas thromboxane 2 (TBXA2) has
been related to platelet aggregation, myocardial ischemia and
bronchoconstriction, PGD2 has been extensively described as
a regulator of body temperature and sleep cycle, vasodilation,
smooth muscles relaxation and bronchoconstriction (60–62).
With regard to the reproductive systems, the inhibition of
TBXAS leads to increased cAMP-dependent steroidogenesis
in Leydig cells (63). As for PGD2, in males it acts as an
activator of the Sox9 gene and is, therefore, pivotal in testicular
organogenesis (64, 65). However, to the best of our knowledge,
nothing is known about the modulatory effects these two
eicosanoids might have on CL function. Strikingly, PGD2 can
undergo spontaneous dehydration into different J prostanoids,
such as 15d-PGJ2 (66, 67). This prostaglandin can mediate
pro-inflammatory mechanisms through different pathways, but
also affects anti-inflammatory responses, mainly through the
nuclear receptor PPARγ (68). Expression of PPARγ decreased
between days 10 and 20 in qPCR analysis, and is an alternative
receptor for several different factors, including eicosanoids and
fatty acids, with regulatory roles in fatty acid metabolism, cell
differentiation and inflammation (69). Among other regulatory
effects, PPARγ has an indirect role in potentiating the expression
of STAR by upregulating cJUN (70). In the CL of pregnant
dogs, it was stably expressed during the whole diestrus (39).
However, here we observed increased expression of this receptor
in early CL stages, similar to the two eicosanoid-synthases
studied. Thus, it seems plausible that also in the dog PPARγ
provides an alternative pathway for possible modulatory effects
of PGD2-derived prostanoids in the CL.
Collectively, our analysis indicates that during the transition
from the early developing to themature CL a decrease in immune
activity and tissue proliferation occurs, expectedly accompanied
by its increased steroidogenic capacity. Additionally, among
the predicted top upstream regulators, different hormones and
PGE2 receptor 2 (PTGER2/EP2) were present, which are known
to exhibit time-dependent changes in their expression in the
CL during canine diestrus (14, 21). Taking into consideration
that these functional changes and the expression of different
genes were previously investigated and/or were expected, as
mentioned elsewhere, the analysis of time-dependent effects
served also as a primary validation of the Next Generation
Sequencing methodology. Besides this, the expression patterns
of TBXAS, PTGDS, FAS/FASLG,NFκB/NFκBIA, THBS1, PPARγ ,
and HSD17B7 in the canine CL were described and discussed for
the first time herein. All of these factors may serve functional
roles in the development of CL in the canine species and thus
constitute topics worthy of more attention in the future.
Treatment-Induced Effects
The functional suppression of COX2, and the consequent
withdrawal of PGs, had variable effects on the different groups
studied. The numbers of DEGs found for each studied time-point
were also variable, being lower in gonadotropin-independent
CL stages (days 5 and 10) than during the transition period
and at gonadotropin dependency (days 20 and 30, respectively).
Interestingly, the highest number of DEGs (1,741) was found in
CL from dogs treated with Previcox for 20 days. This, together
with the absence of genes commonly affected by treatment
in all groups, reinforces the time and developmental stage-
dependent effects of COX2 suppression on CL transcriptional
activity. Furthermore, the presence of possible compensatory
mechanisms for the withdrawal of PGs was suggested previously
(3, 26) and appears to be a part of the inherent regulation of
CL function in the dog. At the same time, the possible presence
of such mechanisms advocates caution in the evaluation and
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interpretation of the results obtained because they might be
induced by these mechanisms, rather than being directly linked
to the function of PGs.
Gonadotropin-Independent Stage of CL
This stage relates to the early, developing CL treated with
Previcox over 5 and 10 days. Large individual and functional
variations in the response to treatment were observed at this time
at the transcriptome level, with fewer genes passing the applied
stringent P-value and FDR criteria. Nevertheless, functional
terms related to cellular movement and division dominated at
day 5 after ovulation in response to Previcox. Additionally, the
predicted activation of cell movement and cytoskeleton-related
pathways was mainly due to the increased expression of factors
like actins, laminin and myosin observed in the transcriptome
analysis. In preceding studies, significant effects of treatment at
this time-point showed decreased expression of STAR, PRLR
and PTGES, the latter one being associated with lower levels of
intra-CL PGE2 (3). However, no significant effects were observed
regarding transcriptional capacity, vascularization or immune
function (24, 26). Here, as detected by qPCR, expression of
the growth factor FGF2 was decreased by Previcox treatment,
while THBS1 was upregulated. Considering the aforementioned
interaction between these factors, the expression pattern of FGF2
and THBS1 suggests a disruptive effect of this treatment on
angiogenic mechanisms. The inhibitory effects on vascularization
appear even more plausible when the increased expression of
TGFβ1 after treatment is considered. In fact, growth and capillary
morphogenesis of endothelial cells isolated from bovine CL were
diminished by this cytokine (71). Additionally, in the present
study qPCR also detected decreased expression of FASLG in
Previcox-treated CL. If, as described above, this factor is usually
associated with anti-angiogenic activity, its increased expression
in early CL stages could imply a positive role of FASLG in
CL angiogenesis, which appears to be affected after treatment.
Although hypothetical, this idea deserves further attention in
the future.
Regarding other functional mechanisms, as indicated by
qPCR, the gene expression of SULT1E1 decreased after Previcox
treatment. As indicated elsewhere, the auto/paracrine effects of
estrogens in the canine CL have been proposed before (6, 46).
SULT1E1 sulfoconjugates estrogens, disrupting their capacity to
bind to their receptors and, in this way, preventing their actions
on target tissues (72). Thus, the observed decrease of SULT1E1
expression in response to treatment might disturb the balance
of locally active estrogens in the CL, presumably as a part of the
compensatory mechanisms following the withdrawal of PGs.
The effects of Previcox treatment on day 10 appeared less
pronounced at the transcriptome level. In previous studies,
however, we observed that inhibition of COX2 at day 10
decreased the expression of PTGES, consequently significantly
decreasing the intra-CL levels of PGE2, and this was associated
with a significant decrease in circulating P4 levels (3, 24). These
previous findings apparently contrast with the low number of
DEGs observed in the present analysis. It appears, however,
plausible that the variation among the treated samples could be
the culprit for the negative output from this analysis, in particular
with regard to the applied adjusted P-value (FDR), accounting for
multiple testing but not for the biological diversity in the response
to the applied anti-COX2 insult.
Transition Toward Gonadotropin Dependence
This stage of the CL relates to the transitional period of
development toward its gonadotropin dependence, represented
in our study by day 20 after ovulation (17, 18). In fact, day
20 was the time-point most affected by treatment. At this time,
the CL appears to be more susceptible to insults targeting its
functionality. The main functional terms overrepresented in
Previcox-treated samples at this day were related to cellular
proliferation and immune response. This fits well with the
previously reported reduced size of the nuclei of steroidogenic
cells and increased expression of some pro-inflammatory
interleukins (e.g., IL1β or IL6) in response to Previcox at this
day (24, 26). In the present NGS analysis, IL1β and IL6 were
also found to be differentially expressed after treatment. The
activation of several immune system-related canonical pathways
was predicted by IPA software, and increased expression of other
pro-inflammatory factors, e.g., ICAM1, NODAL, FAS, FASLG,
and NFκB1, was further confirmed by qPCR. This apparently
increased reactivity of the immune system was accompanied by
negative effects induced by the treatment at this time-point on the
steroidogenicmachinery, mirrored in the decreased expression of
3βHSD and STAR (3, 24). These findings suggest predominantly
negative effects of treatment on CL function at this stage.
With regard to vascular function, in addition to the
previously found increased expression of endothelin-1 (END1)
and downregulation of angiopoietin 1 (ANGPT1) at day 20 of
treatment (26), here, increased expression of the anti-angiogenic
THBS1 and decreased levels of FGF2 were identified. With this,
the postulated negative impact of PGs withdrawal on CL vascular
activity was further substantiated.
Contrasting with the decreased expression of SULT1E1 at day
5 of treatment, its expression was elevated during the transitional
phase at day 20 in the CL of Previcox-treated dogs. SULT1E1
was also elevated in the CL in mid-pregnant dogs undergoing
luteolysis after treatment with an antigestagen (27), suggesting
that the local withdrawal of estrogens could be related with
decreased CL activity. The apparently suppressed expression of
HSD17B7 (P= 0.0608) at day 20 of treatment further strengthens
the idea of possible involvement of estrogens in CL function. On
the other hand, we also observed strongly increased expression of
the nuclear factor NR4A1 (also referred to as Nur77) in response
to Previcox. This expression pattern was further confirmed
by qPCR. Several functions were previously described for this
receptor. The expression of NR4A1 was increased in the CL of
bitches, cows and rats in response to treatment with the luteolysin
PGF2α (73–75). This receptor is also known to be an important
regulator of inflammation [reviewed in (76)]. Thus, it is plausible
that the increased expression of this nuclear receptor might be
related to the increased inflammatory response observed at this
CL stage to the Previcox insult. Nevertheless, its exact functions
in the canine CL remain to be determined. Due to the versatile
effects of NR4A1 in different organs and systems, its possible
actions on the CL appear worthy of more attention in the future.
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The increased expression of TBXAS, PTGDS, and PPARγ
observed in transcriptomic and qPCR analyses at day 20
after Previcox treatment could represent possible compensatory
mechanisms, as suggested in previous reports (3, 26). As
mentioned elsewhere, PPARγ acts as an alternative receptor
for prostaglandins (68, 69). Besides its potential to upregulate
the pro-steroidogenic cJUN (70), it was shown to repress the
activity of NFκB (77, 78). Indeed, increased expression of cJUN
was proposed previously to counteract the negative effects of
Previcox (26).
Cumulatively, in accordance with our previous findings
(26), the functional inhibition of COX2, besides suppressing
intra-CL PGE2 content (3), led to activation of CL immune
system-related factors and pathways. It also negatively affected
vascularization of the CL during its functional transition to the
gonadotropin-dependent stage. The regulatory effects upon
PPARγ and NFκB, the reciprocal interactions between
FGF and THBS or even possible modulatory effects on
locally produced estrogens, could possibly be involved in
the maintenance of CL tissue homeostasis at this time in a
PG-dependent manner.
Gonadotropin-Dependent CL Stage
In this comparison, the stage of CL development refers
to mid-diestrus, represented by day 30. During this time,
the maintenance of CL function is primarily dependent on
PRL (19, 20). Day 30 showed the second highest number
of DEGs in response to Previcox treatment. Also, in the
Venn diagram analysis, days 20 and 30 shared the highest
number of simultaneously affected genes, even if signaling
pathways represented by these genes indicated their different
functional status.
At day 30, the fully mature CL exhibits high steroidogenic
capacity. This was reflected in the functional terms
overrepresented at day 30 in control samples compared
with their Previcox-treated counterparts. These included, e.g.,
steroidogenic and lipid metabolic processes, which were less
represented in the CL of treated dogs. The analysis of functional
pathways corroborated these observations, revealing cholesterol
synthesis and steroidogenesis among the prevalent pathways
affected by the treatment. Interestingly, in this contrast, the
effects of the treatment appeared diverse and affected genes with
higher functional variations. On the other hand, as indicated
above, contrasting with day 20 of treatment, the immune
system-related functional pathways (e.g., NFκB- and TGFβ-
signaling) appeared less represented at day 30 in the treated
CL. Their importance was, however, underlined by placing
their respective associated factors among the top upstream
regulators. Thus, besides TNF and PPARγ, TGFβ1 and NFκBIA
(NFκB-associated factor) were also identified by IPA software.
By adding new information, these results also fit well with
the previously reported increased presence of CD4-expressing
macrophages infiltrating the CL in response to treatment
with Previcox at day 30 of treatment (26). Activation of the
immune system was further indicated in the data set presented
here by the strong suppression of IDO1 expression at day
30 of treatment. Being a rate-limiting enzyme in tryptophan
catabolism, IDO1 function is considered to be a checkpoint in
the activation of leukocytes by exerting immunosuppressive
actions (79). Interestingly, and as indicated above, despite
the proximities in the development time, maturation stage
and steroidogenic capacity of the CL between days 20 and 30
after ovulation, the effects evoked upon the immune system at
these two time-points by Previcox appeared to diverge, further
highlighting the time-dependent effects of PGs withdrawal in the
canine CL.
Final Remarks
As shown in this and previous studies, treatment of dogs
with Previcox affects multiple CL components and functions
(3, 24, 26). In accordance with these observations, broad
effects of COX2 inhibition were observed in the deep RNA-
Seq analysis performed herein. These effects were clearly
stage-dependent. Day 20, marking the transitional period
toward gonadotropin-dependence, was the most affected by
COX2-inhibition, identifying this period as the most sensitive
stage of CL development to functional PGs withdrawal. It
appears that at this stage the intrinsic regulatory mechanisms
become unstable, while the luteotropic effects of PRL may be
affected by treatment (3). This could also affect the strong
compensatory mechanisms present in earlier stages, rendering
the mature CL less capable of stabilizing its transcriptome
in response to the insult caused by Previcox treatment.
Indeed, it appears that the early CL is more resistant to PGs
withdrawal, suggesting that this organ is intrinsically regulated
and bears strong compensatory mechanisms. With maturation
of the CL, its transcriptome becomes more sensitive to
COX2 inhibition.
Mechanisms related to cellular proliferation, immune system
and vascularization are undoubtedly involved in the proper
development of the CL. Accordingly, here, deeper insights have
been provided into the regulatory mechanisms underlying CL
development, identifying several factors and pathways that could
play roles in this process. Some of these, such as THBS1 and
FAS/FASLG, are known for their involvement in the termination
of CL function, but their role in CL formation is still not well-
understood. Additionally, the modulatory effects of estrogens
and PPARγ in the canine CL are still obscure and may play
important luteotropic roles. Finally, the increased expression of
TBXAS and PTGDS in early CL stages supports the idea that other
PGs, besides PGE2, may play an important role in regulating and
supporting the canine CL.
Apparently, by investigating transcriptomic effects, and
being based on gene expression patterns, the information
presented herein is not definitive and further functional and
protein expression-related studies are needed to support
these findings and hypotheses. Nevertheless, our analyses
with Previcox-treated dogs clearly reveal broader regulatory
roles linked to PGs in CL function, besides the luteotropic
support of steroidogenesis by PGE2 or the luteolytic
signaling of PGF2α. With this, the translational aspect of
the present study in relation to other domestic animal species
is obvious.
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Our study falls into the clinical trials category and Previcox
was used orally, as recommended by the manufacturer. This
might have weakened effects on the target tissue due to its
metabolism, even though 10 mg/kg of firocoxib, double the
clinically recommended dosage, was used (in consultation with
the manufacturer regarding safety). Despite causing disturbances
in CL function, in none of the dogs was the luteal phase
terminated. From the clinical point of view, this is important
information because administration of Previcox appears to be
safe for CL function and maintenance in non-pregnant, and
presumably, also in pregnant dogs.
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Supplemental Image 1 | Initial explorative analysis of the sequencing dataset.
Samples correlation matrix and heatmaps were obtained by using CountQC app
provided in the SUSHI framework. In (A,B), “K” and “Ctrl” relate to control samples
while “P” and “Treat” relate to Previcox-treated samples. (A) Sample correlation
matrix containing all samples submitted for RNA-Seq and considering all genes
present. Samples 10/1 (10_K_1) and 30/1 (30_K_1) controls, and 10/2 (10_P_2)
and 30/1 (30_P_1) treated, exhibited low correlation coefficients compared with
other samples from the same group and were removed from further analysis. (B)
Sample correlation matrix containing final list of samples used in the present
analysis and considering all genes present. Control groups appear to have higher
homogeneity than respective treated groups. (C) Heatmap of 2,000 genes with
higher variance among all control samples. Gene ontologies (GOs) shown were
obtained with Enrichr. Samples show apparent better clustering than in (D), the
heatmap of 2,000 genes with higher variance among all samples analyzed
(control and treated).
Supplemental Image 2 | Volcano plots of differentially expressed genes (DEGs;
FDR < 0.1, Log2Ratio > 0.5) affected by the passage of time (A: contrast “days
20+30 control over days 5+10 control”) or induced by treatment (B: contrast “day
5 treated over day 5 control;” C: contrast “day 5 treated over day 5 control;” D:
contrast “day 5 treated over day 5 control”).
Supplemental Image 3 | Functional networks found in the upregulated
differentially expressed genes (DEGs) from the contrast “days 20+30 control over
days 5+10 control” and in the downregulated DEGs from the contrast “day 30
treated over day 30 control.” Functional networks were obtained with the ClueGO
application for Cytoscape. The functional terms overrepresented in each group are
shown. Redundant or non-informative terms were removed and the networks
obtained were manually rearranged. Number of mapped genes is indicated by the
node size while significance of functional terms is denoted by node color
(represented in legend at the right bottom corner). (A) Networks more highly
represented on days 20 and 30 control (mature CL) were related to intracellular
transport and lipid metabolism. (B) Networks more highly represented in CL
samples from control animals on day 30 after ovulation were related to nitric oxide
synthesis and angiogenesis.
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